Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
59
CXXIF Quote, Financials, Valuation and Earnings
Last price:
$0.26
Seasonality move
:
29.23%
Day range:
$0.30 - $0.32
52-week range:
$0.12 - $0.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.15x
P/B ratio:
1.38x
Volume:
16.5K
Avg. volume:
61.9K
1-year change:
53.73%
Market cap:
$37.6M
Revenue:
$30.1M
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CXXIF
C21 Investments, Inc.
|
-- | -- | -- | -- | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $6.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.13 | -- | -43.57% | $55.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CXXIF
C21 Investments, Inc.
|
$0.32 | -- | $37.6M | -- | $0.00 | 0% | 1.15x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.62 | $16.67 | $2.1B | 27.84x | $0.00 | 0% | 8.29x |
|
EDSA
Edesa Biotech, Inc.
|
$1.76 | $10.33 | $12.4M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$1.06 | $6.00 | $23.6M | -- | $0.00 | 0% | 27.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.99 | $5.49 | $105.3M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.19 | $3.5B | -- | $0.00 | 0% | 473.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CXXIF
C21 Investments, Inc.
|
29.29% | 0.221 | 25.88% | 0.52x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CXXIF
C21 Investments, Inc.
|
$3.8M | $1.2M | -6.81% | -9.86% | 14.5% | $422.4K |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
C21 Investments, Inc. vs. Competitors
-
Which has Higher Returns CXXIF or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of 42.95%. C21 Investments, Inc.'s return on equity of -9.86% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital CXXIFC21 Investments, Inc.45.15% -$0.00 $38.7M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About CXXIF or AUPH?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 6.7%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than C21 Investments, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXIFC21 Investments, Inc.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is CXXIF or AUPH More Risky?
C21 Investments, Inc. has a beta of 1.198, which suggesting that the stock is 19.785% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock CXXIF or AUPH?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXIF or AUPH?
C21 Investments, Inc. quarterly revenues are $8.5M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. C21 Investments, Inc.'s net income of -$481.7K is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.15x versus 8.29x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXIFC21 Investments, Inc.1.15x -- $8.5M -$481.7K AUPHAurinia Pharmaceuticals, Inc.8.29x 27.84x $73.5M $31.6M
-
Which has Higher Returns CXXIF or EDSA?
Edesa Biotech, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.86% beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital CXXIFC21 Investments, Inc.45.15% -$0.00 $38.7M EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About CXXIF or EDSA?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 525%. Given that Edesa Biotech, Inc. has higher upside potential than C21 Investments, Inc., analysts believe Edesa Biotech, Inc. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXIFC21 Investments, Inc.0 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is CXXIF or EDSA More Risky?
C21 Investments, Inc. has a beta of 1.198, which suggesting that the stock is 19.785% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock CXXIF or EDSA?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXIF or EDSA?
C21 Investments, Inc. quarterly revenues are $8.5M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. C21 Investments, Inc.'s net income of -$481.7K is higher than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.15x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXIFC21 Investments, Inc.1.15x -- $8.5M -$481.7K EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns CXXIF or LEXX?
Lexaria Bioscience Corp. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of -2178.51%. C21 Investments, Inc.'s return on equity of -9.86% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital CXXIFC21 Investments, Inc.45.15% -$0.00 $38.7M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About CXXIF or LEXX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 403.14%. Given that Lexaria Bioscience Corp. has higher upside potential than C21 Investments, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXIFC21 Investments, Inc.0 0 0 LEXXLexaria Bioscience Corp.0 0 0 -
Is CXXIF or LEXX More Risky?
C21 Investments, Inc. has a beta of 1.198, which suggesting that the stock is 19.785% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock CXXIF or LEXX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXIF or LEXX?
C21 Investments, Inc. quarterly revenues are $8.5M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. C21 Investments, Inc.'s net income of -$481.7K is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.15x versus 27.04x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXIFC21 Investments, Inc.1.15x -- $8.5M -$481.7K LEXXLexaria Bioscience Corp.27.04x -- $174K -$2.7M
-
Which has Higher Returns CXXIF or ONCY?
Oncolytics Biotech, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.86% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital CXXIFC21 Investments, Inc.45.15% -$0.00 $38.7M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About CXXIF or ONCY?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 452.93%. Given that Oncolytics Biotech, Inc. has higher upside potential than C21 Investments, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXIFC21 Investments, Inc.0 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is CXXIF or ONCY More Risky?
C21 Investments, Inc. has a beta of 1.198, which suggesting that the stock is 19.785% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock CXXIF or ONCY?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXIF or ONCY?
C21 Investments, Inc. quarterly revenues are $8.5M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. C21 Investments, Inc.'s net income of -$481.7K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.15x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXIFC21 Investments, Inc.1.15x -- $8.5M -$481.7K ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns CXXIF or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of -867.29%. C21 Investments, Inc.'s return on equity of -9.86% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital CXXIFC21 Investments, Inc.45.15% -$0.00 $38.7M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About CXXIF or XENE?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 22.62%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than C21 Investments, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXIFC21 Investments, Inc.0 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is CXXIF or XENE More Risky?
C21 Investments, Inc. has a beta of 1.198, which suggesting that the stock is 19.785% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock CXXIF or XENE?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXIF or XENE?
C21 Investments, Inc. quarterly revenues are $8.5M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. C21 Investments, Inc.'s net income of -$481.7K is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.15x versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXIFC21 Investments, Inc.1.15x -- $8.5M -$481.7K XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
